279 related articles for article (PubMed ID: 10589768)
1. Circulating soluble Fas concentration in breast cancer patients.
Ueno T; Toi M; Tominaga T
Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
[TBL] [Abstract][Full Text] [Related]
2. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
Konno R; Takano T; Sato S; Yajima A
Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
4. Circulating soluble Fas in patients with breast cancer.
Sheen-Chen SM; Chen HS; Eng HL; Chen WJ
World J Surg; 2003 Jan; 27(1):10-3. PubMed ID: 12557031
[TBL] [Abstract][Full Text] [Related]
5. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.
Ugurel S; Rappl G; Tilgen W; Reinhold U
Clin Cancer Res; 2001 May; 7(5):1282-6. PubMed ID: 11350895
[TBL] [Abstract][Full Text] [Related]
6. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients.
Shimizu M; Kondo M; Ito Y; Kume H; Suzuki R; Yamaki K
Cancer Detect Prev; 2005; 29(2):175-80. PubMed ID: 15829378
[TBL] [Abstract][Full Text] [Related]
7. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
[TBL] [Abstract][Full Text] [Related]
8. Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation.
Bewick M; Conlon M; Parissenti AM; Lee H; Zhang L; Glück S; Lafrenie RM
J Hematother Stem Cell Res; 2001 Dec; 10(6):759-68. PubMed ID: 11798502
[TBL] [Abstract][Full Text] [Related]
9. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer.
Toi M; Taniguchi T; Ueno T; Asano M; Funata N; Sekiguchi K; Iwanari H; Tominaga T
Clin Cancer Res; 1998 Mar; 4(3):659-64. PubMed ID: 9533534
[TBL] [Abstract][Full Text] [Related]
10. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
[TBL] [Abstract][Full Text] [Related]
11. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer.
Yamashita J; Ogawa M; Yamashita S; Nomura K; Kuramoto M; Saishoji T; Shin S
Cancer Res; 1994 Apr; 54(7):1630-3. PubMed ID: 8137271
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
14. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
15. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
16. sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients.
Ulukaya E; Acilan C; Yilmaz M; Yilmaztepe-Oral A; Ari F; Zik B; Ursavas A; Tokullugil AH
Cell Biochem Funct; 2010 Oct; 28(7):565-70. PubMed ID: 20941746
[TBL] [Abstract][Full Text] [Related]
17. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma.
Shering SG; Sherry F; McDermott EW; O'Higgins NJ; Duffy MJ
Cancer; 1998 Dec; 83(12):2521-7. PubMed ID: 9874458
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
Naumnik W; Izycki T; Ossolinska M; Chyczewska E
Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
[TBL] [Abstract][Full Text] [Related]
19. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J
Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
[TBL] [Abstract][Full Text] [Related]
20. Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose.
Tagami A; Ohnishi H; Hughes RD
Hepatogastroenterology; 2003; 50(51):742-5. PubMed ID: 12828076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
